Diagnosis and Healing In Veterans Suspected of Suffering from Post- Traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic ActivationKenneth Blum1,2,3,4,5,6,7*, John Giordano2, Marlene Oscar-Berman7, Abdalla Bowirrat8, Thomas Simpatico9 and Debmalya Barh5
- *Corresponding Author:
- Kenneth Blum
Department of Psychiatry
University of Florida Box 100183 Gainesville
E-mail: [email protected]
Received date: May 05, 2012; Accepted date:May 29, 2012; Published date: May 31, 2012
Citation: Blum K, Giordano J, Oscar-Berman M, Bowirrat A, Simpatico T, et al. (2012) Diagnosis and Healing In Veterans Suspected of Suffering from Post- Traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic Activation. J Genet Syndr Gene Ther 3:116. doi:10.4172/2157-7412.1000116
Copyright: © 2012 Blum K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
There is a need for understanding and treating post-traumatic stress disorder (PTSD), in soldiers returning to the United States of America after combat. Likewise, it would be beneficial to finding a way to reduce violence committed by soldiers, here and abroad, who are suspected of having post-traumatic stress disorder (PTSD). We hypothesize that even before combat, soldiers with a childhood background of violence (or with a familial susceptibility risk) would benefit from being genotyped for high-risk alleles. Such a process could help to identify candidates who would be less suited for combat than those without high-risk alleles. Of secondary importance is finding safe methods to treat individuals already exposed to combat and known to have PTSD. Since hypodopaminergic function in the brain’s reward circuitry due to gene polymorphisms is known to increase substance use disorder in individuals with PTSD, it might be parsimonious to administer dopaminergic agonists to affect gene expression (mRNA) to overcome this deficiency.